Cost-Effectiveness Analysis of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for the Prevention of RSV Illness Among Infants in Hong Kong | Synapse
March 2, 2026Open Access
Cost-Effectiveness Analysis of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for the Prevention of RSV Illness Among Infants in Hong Kong
Key Points
This analysis aims to evaluate the cost-effectiveness of the RSVpreF maternal vaccine in preventing RSV illness among infants.
Conducted a cost-effectiveness analysis using healthcare cost data related to RSV illness in infants.
Evaluated year-round vaccination strategies for maternal immunization in Hong Kong.
Compared economic outcomes of vaccination against RSV illness to determine cost savings.
Year-round vaccination with RSVpreF could significantly lower both clinical cases and healthcare expenditures among infants.
The program is deemed cost-effective, indicating that it saves money while improving health outcomes.
Abstract
Year-round RSVpreF maternal vaccination would substantially reduce RSV's clinical and economic burden among infants in Hong Kong and would be a cost-effective program.